Mani Foroohar

Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine in development — mRNA-1273 — continues to inspire confidence among sell-side analysts. The Moderna Analyst: SVB Leerink analyst Mani Foroohar initiated coverage of Moderna with a Market Perform rating and $65 price target. The...

With more and more genetic medicine companies going commercial, Leerink turned its attention to the sector this week.  The Analyst Leerink’s Mani Foroohar initiated coverage of 10 genetic medicine companies with the following ratings and price targets: bluebird bio (NASDAQ:...